
    
      The author aims to evaluate the effects of two regimens (everolimus-based versus
      tacrolimus-based) in kidney transplantation recipients. Both of regimens are prescribed only
      in recipents who have low immunologicla risks. After informed consent, all eligible
      recipients will be collected blood and urine sample for microRNA profile testing during study
      periods.
    
  